AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01109225 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: urine sample
Study NCT01109225 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulmonary echography
Study NCT02697656 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-help
Description: Self-help resources on obtaining employment and coping with chronic pain
Study NCT02697656 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Transdisciplinary treatment at the pain clinic. This includes medical, psychological and physiotherapy treatment.
Study NCT02697656 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Transdisciplinary treatment at the pain clinic. This includes medical, psychological and physiotherapy treatment.
Study NCT00652600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: ER Capsules, 160 mg, single-dose
Study NCT00652600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inderal-LA
Description: ER Capsules, 160 mg, single-dose
Study NCT01109225 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vascular check
Study NCT01109225 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: renal echography
Study NCT03471195 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Total Salivary Cytokine profile
Description: Saliva will be collected using the passive drool technique and stored in a deep freezerat-60C.
Study NCT01553617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution (VolulyteTM)
Description: Study drug will be given as part of priming of the ECC and for volume therapy up to the maximum dosage of 50 mL/kg body weight/day
Study NCT01553617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human serum albumin
Description: Control drug will be given as part of priming of the ECC and for volume therapy up to the maximum dosage of 50 mL/kg body weight/day
Study NCT01560429 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient controlled epidural analgesia
Description: Continuous epidural infusion rates were set to maintain pain scores of ≤ 3 on a numeric rating scale (NRS) of 0 to 10 while in the post anesthesia care unit (PACU) following thoracotomy. Once stabilized patients were switched to Patient controlled epidural analgesia (PCEA) which meant they continued to receive 2/3rds of the dose as continuous background epidural infusions but they had the option to receive the remaining 1/3rd dosage via PCEA.
Study NCT01560429 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous epidural analgesia
Description: The continuous epidural analgesia (CEA) infusion rates were titrated to achieve pain scores of ≤ 3 on a numeric rating scale (NRS) of 0 to 10 while in post-anesthesia care unit (PACU) (as described for the PCEA group above). Those allocated to the CEA group remained on the same continuous epidural analgesia infusion which maintained the pain scores at ≤ 3.
Study NCT01137682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide
Description: * Double-blind pasireotide LAR 40 mg i.m. injection once every 28 ± 2 days for 24 weeks or~* Double-blind pasireotide LAR 60 mg i.m. injection once every 28 ± 2 days for 24 weeks
Study NCT01137682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: octreotide LAR 30mg
Description: In an open-label, active control arm, continue on the same treatment with octreotide LAR 30 mg every 28 ± 2 days as received for at least 6 months prior to randomization
Study NCT01137682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lanreotide ATG 120mg
Description: In an open-label, active control arm, continue on the same treatment with lanreotide ATG 120 mg every 28 ± 2 days as received for at least 6 months prior to randomization
Study NCT02362789 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: 150 mg secukinumab in 1 ml solution for subcutaneous injection (pre-filled syringe)
Study NCT02362789 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo in 1 ml solution for subcutaneous injection (pre-filled syringe)
Study NCT02684136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suvorexant
Description: suvorexant 20 mg taken before sleep
Study NCT02684136 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo taken before sleep
Study NCT02926118 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low glycemic load
Description: Low glycemic load diets will be consumed at breakfast, lunch and dinner for three consecutive days
Study NCT02926118 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High glycemic load
Description: High glycemic load diets will be consumed at breakfast, lunch and dinner for three consecutive days
Study NCT02066636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT05205213 — intervention group
Intervention type: OTHER
Intervention: Surgical Technique (lateral retromuscular preperitoneal)
Description: Open abdominal wall repair through the previous lateral incision for L3-L4 Incisional hernias
Study NCT01981447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Lacosamide
Description: Lacosamide administered intravenously over 15 or 30 minutes, depending on study arm, to patients with epilepsy.
Study NCT03545893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 600 mg
Description: Ibuprofen 600mg prescription, to be taken 1 tablet as needed every 6 hours for pain.
Study NCT00878007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intermittent screening and treatment for malaria
Description: All children will be screened for malaria using rapid diagnostic tests (RDTs) once a term (thrice yearly). Children (with or without clinical malaria symptoms) found to be RDT-positive will be treated with artemether-lumefantrine according to national guidelines. Screening and treatment will be administered by district public health staff once a school term, observed by the evaluation research team.
Study NCT00878007 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teacher training on literacy instruction
Description: Education intervention designed to improved early grade literacy instruction, focusing on phonological awareness \& vocabulary and relationship between letters and sounds in a systematic and explicit fashion. Specific interventions will include training on (i) how to monitor students' progress in large classes (ii) developing and using instructional materials for reading (iii) lesson planning for explicit teaching of letter-sound relationships (iv) instructional techniques for large classes.
Study NCT02384629 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCT-guided PCI with conventional DES (Biomatrix flex stent)
Description: BioMatrix Flex is abluminal biodegradable polymer DES. Its abluminal coating is absorbed after 6 to 9months and turns the DES into a BMS. It combines the proven safety of a DES with an abluminal biodegradable polymer, the prove efficacy of BA9 and an advanced stent design. Optical coherence tomography (OCT), has enabled the evaluation of strut coverage and arterial healing after DES implantation with a superior resolution and delineation over other imaging modalities. With using these superiorities of OCT, there have been many studies assessing the neointimal coverage following various types of DES implantation in various periods.
Study NCT02384629 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angio-guided PCI with AXXESS stent
Description: The AXXESS stent (Biosensors Europe SA, Morges, Switzerland) is a dedicated self-expanding bifurcation stent eluting the sirolimus analog Biolimus A9 emulsed in a biodegradable polymer. It has the advantage to preserve the ostium of both distal branches and allows additional stent implantation in the distal branches for complete lesion coverage, while reducing large stent overlap and eliminating deformation. We use the conventional coronary angiography.
Study NCT02384629 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angio-guided PCI with PCI with conventional DES (Biomatrix flex stent)
Description: BioMatrix Flex is abluminal biodegradable polymer DES. Its abluminal coating is absorbed after 6 to 9months and turns the DES into a BMS. It combines the proven safety of a DES with an abluminal biodegradable polymer, the prove efficacy of BA9 and an advanced stent design. We use the conventional coronary angiography.
Study NCT00561028 — intervention group
Intervention type: OTHER
Intervention: blood sample analysis - mycoplasma and chlamydia antibodies
Description: Anti-Chlamydia and anti-Mycoplasma IgG antibodies were measured by indirect immunofluorescence at baseline (24 hours of hospitalization) and after 6 months (follow-up).
Study NCT00579527 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cultured Thymus Tissue for Implantation (CTTI)
Description: Potential thymus recipient subjects are screened for eligibility. Thymus donor (unrelated donor), and thymus donor's birth mother are screened for safety. CTTI is done under general anesthesia in the operating room. Cultured thymus tissue is implanted into the subject's quadriceps. Two to three months post CTTI, if medically stable, the subject undergoes allograft biopsy. At the time of implantation and biopsy, a skin biopsy is done. Immunosuppression is weaned as per protocol.
Study NCT00878007 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IST plus literacy instruction programme
Description: Schools will receive both IST and the literacy instruction programme
Study NCT04218227 — intervention group
Intervention type: BEHAVIORAL
Intervention: Self-hypnosis/self-care group
Description: Self-hypnosis/self-care
Study NCT00579527 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cultured Thymus Tissue Implantation and Parental Parathyroid Transplantation
Description: For subjects w/ hypoparathyroidism, the subject may receive CTTI and parathyroid transplant. For parathyroid transplant, parental parathyroid donors are screened. Parathyroid is harvested from the parent who shares the most Human Leukocyte Antigens (HLA) alleles with the thymus donor. Parathyroid gland is minced and placed in quadriceps muscle; there is no dose. Parathyroid donors are monitored as outpatients until recipients' discharge. Recipients' calcium and PTH levels are monitored indefinitely. Potential thymus recipient subjects are screened for eligibility. Thymus donor (unrelated donor), and thymus donor's birth mother are screened for safety. CTTI is done under general anesthesia in the operating room. Cultured thymus tissue is implanted into the subject's quadriceps. Two to three months post CTTI, if medically stable, the subject undergoes allograft biopsy. At the time of CTTI and biopsy, a skin biopsy is done. Immunosuppression is weaned as per protocol.
Study NCT00579527 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Draw
Description: Birth mothers of Thymus Recipients are asked to participate in the study and undergo phlebotomy to allow testing of T cell identity in the Complete DiGeorge subjects. If blood is not obtainable then a buccal swab may be done.
Study NCT00579527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabbit anti-thymocyte globulin
Description: Three doses of 2 mg/kg IV (through a central venous catheter) prior to CTTI. Each dose of Rabbit anti-thymocyte globulin (RATGAM) is given over 12 hours. RATGAM is usually given on days-5, -4, and -3 prior to CTTI or CTTI and parathyroid transplantation. Medications (diphenhydramine, steroids, and acetaminophen) are given with rabbit anti-thymocyte globulin.
Study NCT00579527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: In addition to RATGAM, subjects with typical cDGA with PHA responses >50,000 cpm, or atypical cDGA with PHA response \<75,000cpm (when not on immunosuppression) or \<40,000 cpm to PHA while on immunosuppression, are started on cyclosporine (Csa) as soon as cDGA is diagnosed. Csa is continued with target trough levels of 180 to 220 ng/ml. If subject cannot tolerate Csa, Csa may be changed to tacrolimus (FK506) with target trough level 7 to 10 ng/ml. When trough levels are outside of range, dosing is modified appropriately.~Csa may be given every 8 to 12 hours enterally or IV before and after CTTI. The Csa dose is dependent on T cell numbers and the target Csa trough levels. Csa is weaned as per protocol.
Study NCT00579527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: If unable to tolerate cyclosporine, then tacrolimus is given. Tacrolimus may be given every 8 to 12 hours enterally or IV before and after the CTTI transplant. Tacrolimus dose is dependent on the T cell numbers and the target tacrolimus trough levels. Tacrolimus is weaned as per protocol.
Study NCT00579527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone or Prednisolone
Description: Steroids IV or enterally may be given before and after CTTI or CTTI and parathyroid transplantation. Administration and dosage depends on T cell numbers and symptoms. Pre-transplant steroids may be used when pre-transplant T cells >4,000cumm. Steroids are weaned as per protocol.
Study NCT00579527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclizumab
Description: In addition, subjects with Atypical DiGeorge with PHA responses >75,000cpm while on no immunosuppression or PHA responses >40,000cpm while on immunosuppression, Daclizumab 1 mg/kg single dose IV may be given depending on T cell counts. Administration of Daclizumab depends on T cell numbers and T cell activation. A single dose may be given after the administration of rabbit anti-thymocyte globulin and before CTTI. If Daclizumab is not given before CTTI, and, depending on the T cell numbers and T cell activation, a single dose of Daclizumab may be given 3-5 days after CTTI.
Study NCT00579527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: In addition, subjects with Atypical DiGeorge with PHA responses >75,000cpm while on no immunosuppression or PHA responses >40,000cpm while on immunosuppression, Mycophenolate mofetil 15 mg/kg/dose every 8 hours IV or enterally may be given depending on T cell counts. Mycophenolate mofetil may be given if the T cell count remains elevated 5 days after CTTI. If MMF is given, the dose is 15 mg/kg IV. MMF may be stopped at 35 days after CTTI or continued for up to six months after CTTI.
Study NCT04218227 — intervention group
Intervention type: BEHAVIORAL
Intervention: Music/self-care
Description: Music-therapy/self-care
Study NCT04218227 — intervention group
Intervention type: BEHAVIORAL
Intervention: Self-care
Description: Self-care
Study NCT04218227 — intervention group
Intervention type: BEHAVIORAL
Intervention: Psycho-education
Description: Psycho-education
Study NCT04218227 — intervention group
Intervention type: BEHAVIORAL
Intervention: Self-hypnosis/self-care motivation
Description: Motivation to learn self-hypnosis/self-care
Study NCT03794557 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Water Injection
Description: Inhaled Sterile Water Injection
Study NCT03794557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PUL-042 Inhalation Solution
Description: PUL-042 Inhalation Solution
Study NCT01391390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 10mg/day, 12-week treatment
Study NCT01391390 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10mg/day, 12-week treatment for TD
Study NCT02195076 — intervention group
Intervention type: OTHER
Intervention: non-invasive detection of cancer odor
Description: The odor VOCs of the specimens will be subjected to our system for detection by the biosensors. If the sample is cancerous the biosensors will report it (YES signal). If the sample s not cancerous, the biosensors will not report it (NO signal).
Study NCT02211001 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates Group
Description: The exercises were applied once a week during eight weeks.
Study NCT02343991 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial ExABlate
Description: MR Guided Focused Ultrasound
Study NCT01049152 — intervention group
Intervention type: DEVICE
Intervention: Continuous Glucose Monitoring (CGM)
Description: CGM allocated one time for 3 days
Study NCT00796172 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Adherence System (MAS)
Description: Participants will receive individualized reports from the MAS and counseling from their doctors. The counseling will focus on adherence to blood pressure and cholesterol management medications.
Study NCT00796172 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will receive usual care from their doctors and written materials on CVD risk factors.
Study NCT02670395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54416076
Description: JNJ-54416076 suspension will be administered orally.
Study NCT02670395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo solution will be administered orally.
Study NCT01643889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A (domperidone 10 mg)
Description: 1 domperidone 10 mg capsule four times a day (q.i.d.) + 1 domperidone placebo capsule q.i.d. on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.
Study NCT02211001 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Segmented Dynamic Exercises Group
Description: The exercises were applied once a week during eight weeks. once a week for eight weeks.
Study NCT02211001 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Global Postural Reeducation
Description: The exercises were applied once a week during eight weeks.
Study NCT00638313 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be given either Placebo or PF-04603629.
Study NCT00638313 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04603629
Description: Subjects will be given either Placebo or PF-04603629. The specific dose of PF-04603629 given depended on the Cohort to which the patient was assigned. Doses administered ranged from 1 mg to 70 mg.
Study NCT00637507 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-frequency Oscillation and Tracheal Gas Insufflation
Description: Patients will receive daily sessions of High-frequency Oscillation and Tracheal Gas Insufflation (HFO-TGI), which will last at least 6 hours. These sessions will comprise a recruitment period of at least 90 min, a stabilization period of at least 4 hours, and a weaning period of at least 60 min. The HFO-TGI strategy will be aimed at initially maximizing PaO2/FiO2 without causing hemodynamic compromise (e.g., >10% reduction in cardiac output/index), and subsequently maintaining PaO2/FiO2 >150 mm Hg, while gradually reducing mPaw to 4-6 cm H2O below its initial setting. The weaning from TGI and HFO will be according to the reversal of the oxygenation criterion that mandated their use (see also Detailed Description).
Study NCT00605475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Canakinumab given as single dose IV injection of 0.03 mg/kg, or single dose IV infusion at doses of 0.1 mg/kg 0.3 mg/kg, 1.5 mg/kg or 10 mg/kg.
Study NCT00605475 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to Canakinumab given as single dose IV injection of 0.03 mg/kg, or single dose IV infusion at doses of 0.1 mg/kg 0.3 mg/kg, 1.5 mg/kg or 10 mg/kg.
Study NCT00605475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants continued on their stable daily dose of metformin throughout the study
Study NCT00605475 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Participants continued on their stable daily dose of metformin throughout the study
Study NCT00775931 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: umbilical cord blood transplantation
Description: Umbilical cord blood will be collected, processed and shipped according to existing protocols. 2 cord blood units will be utilized if available. The choice of units will be based on the HLA typing standards of the University of Minnesota Blood and Marrow Program. If 2 units are not available, a single unit may be used. If a single unit is used, the unit should provide at least 10 x 107 nucleated cells/kg recipient body weight.
Study NCT00775931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Campath-1H
Description: Campath-1H will be administered 0.3 mg/kg subcutaneously per day for three days starting on Day -21 through Day -19.
Study NCT00775931 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Total Lymphoid Irradiation
Description: Dose 500 cGy via anteroposterior (AP) and posteroanterior(PA) fields (250 cGy AP and 250 cGy PA).
Study NCT00775931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide (50 mg/kg/dose) will be given IV on day -4, -3, -2 and -1 over 2 hours. The total dose to be given over 4 days is 200 mg/kg for cord blood grafts-receiving patients only.
Study NCT00775931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan
Description: patients\<12 kg: 1.1 mg/kg/dose IV every 6 hours for 8 doses total; patients >12 kg: 0.8 mg/kg/dose IV every 6 hours for 8 doses. on Day -8 to -7 for donor grafts-receiving patients, and on Day -9 to -6 for cord blood grafts-receiving patients.
Study NCT03545893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OxyCODONE 5 Mg Oral Tablet
Description: Oxycodone 5mg Oral Tablet prescription, to be taken 1-2 tablets as needed every 6 hours for pain.